Goldman Sachs Group Inc Procept Bio Robotics Corp Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 350,520 shares of PRCT stock, worth $11.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
350,520
Previous 410,423
14.6%
Holding current value
$11.9 Million
Previous $23.9 Million
15.57%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding PRCT
# of Institutions
290Shares Held
44MCall Options Held
236KPut Options Held
91.9K-
Vanguard Group Inc Valley Forge, PA5.25MShares$178 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$118 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY2.16MShares$73.2 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.53MShares$51.9 Million0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.32MShares$44.9 Million0.01% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $1.51B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...